Upper Endoscopy: Difference between revisions

From PedsAnesthesiaNet
Jump to navigation Jump to search
No edit summary
Tags: Mobile edit Mobile web edit
No edit summary
 
Line 2: Line 2:


[https://pubmed.ncbi.nlm.nih.gov/9768765/ Gastric contents in children presenting for upper endoscopy]
[https://pubmed.ncbi.nlm.nih.gov/9768765/ Gastric contents in children presenting for upper endoscopy]
Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. The New England journal of medicine 2024;390(24):2239-2251. (In eng). DOI: 10.1056/NEJMoa2312282.
2.            Rothenberg ME, Dellon ES, Collins MH, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2023;8(11):990-1004. (In eng). DOI: 10.1016/s2468-1253(23)00204-2.

Latest revision as of 12:24, 23 July 2024

This is a Stub Notice. This page has not been completed. You can work on this page by signing in and going to the Edit tab. Thanks for helping to make PedsAnesthesia.Net Wiki useful.

Go to the Main Page to see the Topic Outline.

Go to the Generalized Suggested Outline for information on case-specific details for each page.

Go to the Test Page for examples on how to use references in the page.


Relevant Article Depot:


Gastric contents in children presenting for upper endoscopy

Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. The New England journal of medicine 2024;390(24):2239-2251. (In eng). DOI: 10.1056/NEJMoa2312282.

2. Rothenberg ME, Dellon ES, Collins MH, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2023;8(11):990-1004. (In eng). DOI: 10.1016/s2468-1253(23)00204-2.